Nextera at the BIO International Convention June 2024! Nextera is attending the BIO International Convention in San Diego June 3 – 6, 2024! Please get in touch if you would like to meet our CEO/CSO Geir Åge Løset and our Head of BD Francis Y. and learn more about our approach in engineered TCR-Like antibody guiding towards pHLA targets with transformational potential in autoimmunity and oncology! Schedule a meeting here: https://lnkd.in/eEDtKaAK #BIO2024 #Innovation #HealthInnovation #NetworkingEvent #Autoimmunity #Oncology #Biopharma #ScienceAndBusiness #SanDiego
Nextera AS’ Post
More Relevant Posts
-
🕰️Why wait hours for results when we can deliver within minutes? Our biobank delivers unparalleled speed with an ischemic time under 10 minutes, which sets new benchmarks in your cancer research. With our proprietary global clinical network, we ensure top tier biospecimen quality and excellence in delivering results for your drug discovery program. Learn more https://bit.ly/3Uj4Olb #biobanking #oncology
-
Alligator Bioscience AB’s two 4-1BB agonists, ATOR-1017 and ALG.APV-527, are featured in this brand new review describing the potential and challenges in developing safe and efficacious 4-1BB agonist and how such molecules could become gamechanger in immune-oncology. We successfully completed phase 1 with ATOR-1017 in H2 2022, and we initiated phase 1 studies with ALG.APV-527 Q1 this together with our partners at Aptevo Therapeutics Inc. We look forward to share data with you as we move these programs forward You can find the full paper here https://lnkd.in/eizNEfF2 #41BB #immunooncology #cancerresearch #phase1 #alligator #review #frontiers #oncology #tcells
-
-
Explore the top targets and the number of products in the bispecific antibody space with curated analytics by LARVOL CLIN. 🧬 Stay ahead with detailed insights into the evolving landscape of antibody therapeutics. Explore more here: https://bit.ly/4bFSDpD #BispecificAntibodies #LARVOLCLIN #BiotechInsights #CancerData #Oncology
-
-
I'm very pleased to serve on the Clinical and Regulatory Advisory Board of AffyImmune Therapeutics - Hagop Youssoufian https://lnkd.in/dprenUyF #Cancer #Career #CARTTherapies #LungCancer #OncoDaily #Oncology #ThyroidCancer #Biotechnology
-
-
Illumina Connected Insights version 4.0 is out! Now supporting variant interpretation for somatic oncology assays at scale, enabling - powerful visualizations of fusions and other variants called from #DRAGEN; integration of #OncoKB, and more than 55 other knowledge sources; and new automation to help predict #oncogenicity based on recent guidelines. #Oncology #NGS #Bioinformatics #Interpretation https://lnkd.in/gBR5syP6 #sequencing #bioinformatics Illumina
-
-
ddPCR technology is a powerful tool for numerous oncology research applications, including monitoring circulating tumor DNA (ctDNA) to assess molecular residual disease (MRD). Did you know Bio-Rad offers an extensive portfolio of assays designed and optimized for Droplet Digital PCR to power your oncology research? With hundreds of wet-lab validated mutation and copy number variation assays, multiplex mutation screening kits, and custom design tools, it's easy to introduce the unparalleled sensitivity and accuracy of ddPCR to your projects. Check out this video to learn more: https://ow.ly/eFt050RhAgZ #DidYouKnow #ddPCR #Oncology
Did You Know that Bio-Rad Offers an Expansive Menu of Oncology Assays Designed & Optimized for ddPCR
https://www.youtube.com/
-
🌞 Ready to start the day at Frühjahrstagung ÖGPath in Vienna, Austria (7-9 March). Come say hi to Didier and learn more about our oncology test portfolio 🙋♂️ Want to be sure to get a slot? Book a meeting with us! 👉 https://lnkd.in/emzsJcvk https://lnkd.in/e5kGZzM6 #oncology #biocartis #diagnostics
-
-
Our reporter Adam Zamecnik is at the Clinical Trials in Oncology Europe 2023 conference in Munich, Germany. He is particularly interested in hearing more about how new technologies can transform the oncology clinical study landscape and improve patient experience. #biotech #pharma #oncology #clinicaltrialsinoncology
-
-
The desire to capture the promise of AI in healthcare is accelerating the need to integrate technology with patient safety. We at N-Power Medicine, Inc. are aligned with the healthcare providers that first we have the duty to do no harm. Therefore, we are “Re-inventing the How” as we know data is only as good as its source – our advisor Michael Seiden MD, PhD, in conversation with our CEO Mark Lee so clearly articulated that “we need comprehensive, well-articulated datasets that look at the entire cancer journey.” With an eye on that N-Power Medicine, Inc. is creating a research-ready integrated platform to generate important insights for clinical research and accelerate drug development. #AI #Cancer #Research #ClinicalTrials
Here’s a sneak peek at the first installment of our upcoming video series, “Re-inventing the ‘How’” featuring N-Power’s CEO Mark Lee, MD, PhD and Michael Seiden MD, PhD, N-Power advisor and former President of the US Oncology Network, as they highlight the need for a new integrated model of clinical research and routine care in community oncology to accelerate drug development. Learn more about N-Power: https://lnkd.in/gJESRx3g #oncologyresearch #cancerresearch #realworlddata #HealthcareAI #oncologydrugdevelopment #RWE #Oncology
-
On demand webinar on organoid drug screening! Click below to access. #OncoPro #Oncology #3Dmodeling
Now available on demand 📽 – Advancing cancer organoid drug screening with novel medium systems If you missed the live webinar, you can now review it on-demand and download the presentation slides to learn about some exciting innovations in tumoroid culture! Access the recorded webinar and presentation here > https://lnkd.in/gJEqpaEW
-
